Description
Preductal MR (Trimetazidine) Coated Tablets 35 mg. №60
Ingredients
- Active ingredient: Trimetazidine 35 mg
Dosage
- Dosage: The usual dose is 1 tablet twice a day, preferably taken with meals.
Indications
- Indicated for: Symptomatic treatment of chronic stable angina pectoris.
Contraindications
- Do not use if: Hypersensitivity to trimetazidine or any other component of the product.
Directions
- Directions for use: Swallow the tablet whole with a sufficient amount of water. Do not crush or chew the tablet.
Scientific Evidence
Trimetazidine, the active ingredient in Preductal MR, optimizes myocardial metabolism by shifting from fatty acid oxidation to glucose utilization. This mechanism improves myocardial efficiency, reduces heart muscle oxygen consumption, and has shown efficacy in enhancing exercise capacity and quality of life in stable angina patients.
Additional Information
Preductal MR is part of a comprehensive angina treatment plan that includes lifestyle modifications and other prescribed medications. Regular monitoring by a healthcare professional is crucial to assess treatment effectiveness and adjust dosages if necessary.
Pharmacological Effects
Trimetazidine’s action optimizes cellular metabolism during ischemia, leading to improved cardiac function and reduced ischemic damage. By modulating energy pathways, it helps maintain the heart muscle’s oxygen supply-demand balance, making it beneficial in angina management.
Clinical Trials and Comparative Effectiveness
Clinical trials have demonstrated trimetazidine’s effectiveness in reducing angina symptoms and enhancing exercise tolerance in stable angina patients. Compared to other anti-anginal agents, trimetazidine offers a unique mechanism of action with minimal hemodynamic effects, making it a well-tolerated option for long-term angina management.
